Lenalidomide

SKU: orb1307920

Featured

Description

Lenalidomide is an orally active immunomodulatory agent that functions as a cereblon (CRBN) ligand. It induces the CRBN-CRL4 E3 ubiquitin ligase to selectively target and degrade the transcription factors IKZF1 and IKZF3. This mechanism underpins its research applications in hematology, immunology, and as a foundational component in PROTAC development for targeted protein degradation studies.

Research Area

Cardiovascular Research, Immunology & Inflammation

Images & Validation

−

Key Properties

−

CAS Number	191732-72-6
MW	259.26
Purity	>98%
Formula	C₁₃H₁₃N₃O₃
SMILES	NC1=C2CN(C3CCC(=O)NC3=O)C(=O)C2=CC=C1
Target	Ubiquitin ligase
Solubility	Soluble in DMSO (up to 30 mg/ml).

Bioactivity

−

Target IC50	TNF-α:13 nM\|HMCL ALMC-1 cells viability:2.6 μM\|MM.1S cells proliferation:81 nM
In Vivo	METHODS: To test the antitumor activity in vivo, Lenalidomide (25 mg/kg) was injected intraperitoneally into C57BL/KaLwRij or B6-SCID mice bearing 5TGM1 tumors once daily for 21 days. RESULTS: Lenalidomide inhibited tumor growth and prolonged survival of C57BL/KaLwRij mice bearing 5TGM1 tumors.Lenalidomide significantly increased the number of IFN-γ-secreting CD4+ and CD8+ T cells but had no effect on NK cells and B cells in the B6-SCID mouse model. Lenalidomide slightly decreased the number of CD25+Foxp3+ T cells in vivo, but increased perforin expression in CD8+ T cells.Lenalidomide promoted type 1 antitumor immune responses in vivo. Read more...
In Vitro	METHODS: Six malignant glioma cell lines, A-172, AM-38, T98G, U-138MG, U-251MG, and YH-13, were treated with Lenalidomide (0.01-100 µM) for 72 h, and cell counts were detected by Coulter counter assay. RESULTS: Lenalidomide inhibited cell counts of all malignant glioma cells in a concentration-dependent manner. METHODS: DCs were differentiated from BM CD14+ cells from MM patients, treated with Lenalidomide (0.1-1 µM) for 8 days and analyzed for DC maturation markers by flow-cytometry. RESULTS: Despite a reduction in the number and percentage of mature DCs, Lenalidomide significantly increased the expression of HLA-DR, CD86, and CD209 in DCs derived from BM over the range of concentrations achieved in MM patients. Read more...
Cell Research	The human NSCLC cell lines Lu-99, H1299, A549, EBC1, and H460 were cultured in RPMI-1640 medium containing 10% fetal bovine serum and antibiotics at 37°C in a humidified chamber containing 5% CO2. Cells were seeded into 60-mm culture dishes (2x10^5 cells per dish) with various concentrations of lenalidomide and incubated for various times . Read more...
Animal Research	Mice were administered sterile preparations of lenalidomide normalized to body weight. Intravenously (IV) dosed animals received drug by bolus tail vein injections, and extravascularly dosed mice received drug by bolus intraperitoneal injections (IP) or oral gavage (PO). Dosing solution, concentrations were adjusted so dose volumes ranged between approximately 100 and 150 μL for IV injections and between approximately 150 and 250 μL for IP and PO dosing in the pharmacokinetic study. However, for the range-finding study, increased dose volumes were used (up to 200 μL IV, 300 μL IP, and 600 μL PO, per approved animal use protocol) to explore elevated lenalidomide doses. The bolus injection rates for all IV, IP, or PO injections were less than 5 s. Concentrations of dosing solutions were verified by liquid chromatography-mass spectrometry . Read more...

Storage & Handling

−

Storage	RT
Expiration Date	12 months from date of receipt.
Disclaimer	For research use only

Alternative Names

−

CC-5013

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at support@biorbyt.com.

Compound Identifiers

PubChem CID

216326 ↗

Key Properties

−

No computed properties available.

Documents Download

Datasheet

Product Information

Download

Request a Document

Protocol Information

Find More Protocols

Lenalidomide (orb1307920)

Based on 0 reviews

Participating in our Biorbyt product reviews program enables you to support fellow scientists by sharing your firsthand experience with our products.

No reviews yet

CAS Number:	17643-36-6
MW:	154.25
Formula:	C₁₀H₁₈O

CAS Number:	3021581-79-0
MW:	790.89
Formula:	C₄₁H₄₂N₈O₇S

MW:	897.98
Formula:	C₄₇H₅₁N₁₁O₈

CAS Number:	1001264-73-8
MW:	488.84
Formula:	C₂₁H₂₈Cl₃N₅O₂

CAS Number:	2052301-24-1
MW:	272.3
Formula:	C₁₅H₁₆N₂O₃

Lenalidomide

Description

Research Area

Images & Validation

Key Properties

Bioactivity

Storage & Handling

Alternative Names

Similar Products

9-Decyn-1-ol [orb1909241]

Abd110 [orb2567127]

L18I [orb2665228]

Ipatasertib-NH2 dihydrochloride [orb1692044]

BTX161 [orb1689545]

Quality Guarantee

Compound Identifiers

Key Properties

Documents Download

Request a Document

Protocol Information

Lenalidomide (orb1307920)

Step 1: Enter information below

Step 2: Enter the in vivo formulation

Available Sizes

Email

UK Office

US Office

CN Office

Distributors